Needham Maintains Buy Rating on Medtronic Amid Renal Device Growth
Needham reiterated its 'Buy' rating for Medtronic (MDT) with an updated $101.00 price target, citing progress in the company's renal denervation business and potential revenue growth from Symplicity Spyral sales. The firm noted that Medicare coverage began in October 2025 after FDA approval in November 2023.
Topics: FDA Approval Medical Devices Medicare Coverage Renal Denervation